Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy

In our case, the use of a low intravenous bolus dose of rFVIIa (recombinant factor VII activated; 15‐20 mcg/kg) was effective and uneventful in controlling late postprocedural PDT bleeding associated with thrombocytopenia that cannot be corrected and after all other treatments failed.

Detalles Bibliográficos
Autores principales: Nicosia, Dario, Federico, Antonino, Vigna, Ivan, Iozzo, Pasquale, Misseri, Giovanni, Cortegiani, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452479/
https://www.ncbi.nlm.nih.gov/pubmed/30997059
http://dx.doi.org/10.1002/ccr3.2061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452479/
https://www.ncbi.nlm.nih.gov/pubmed/30997059
http://dx.doi.org/10.1002/ccr3.2061

Ejemplares similares